Polymorphisms increased risk for steatosis in HCV genotype 1

Phospholipase domain containing 3, or PNPLA3, polymorphism was a predictor for steatosis among Spanish patients with hepatitis C virus genotype 1, according to study data.

Researchers from various medical centers in Spain sought to determine the relationship between PNPLA3 and steatosis and fibrosis after therapy with pegylated interferon plus ribavirin among a cohort of patients with HCV. 

“Liver steatosis is frequent among patients with chronic hepatitis C virus; its prevalence is higher than general population and individuals with other chronic liver diseases,” the researchers wrote


Labels: , , ,